Pacer Advisors
ITOS

Pacer Advisors’s iTeos Therapeutics ITOS Stock Holding History

Pacer Advisors’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-205
Closed -$3.04K – 2625
2024
Q2 		$3.04K Buy
+205
New +$2.94K ﹤0.01% 3668
2022
Q2 		– Sell
-443,460
Closed -$14.3M – 2413
2022
Q1 		$14.3M Buy
+443,460
New +$16.1M 0.12% 167
2021
Q2 		– Sell
-640
Closed -$22K – 1479
2021
Q1 		$22K Buy
+640
New +$23.1K ﹤0.01% 1501

Other funds holding ITOS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Pacer Advisors's ITOS Position: Q3 2024 in Review

Pacer Advisors sold out of iTeos Therapeutics (ITOS) in Q3 2024, closing a stake of 205 shares — an estimated $3.04K sold.

Pacer Advisors first reported a position in ITOS in Q1 2021 and held it in 3 quarters. The position peaked at $14.3M in Q1 2022. 150 funds tracked by Wall St. Rank hold ITOS as of Q3 2024.

  • Pacer Advisors reported no remaining iTeos Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Pacer Advisors sold 205 iTeos Therapeutics shares in Q3 2024, an estimated $3.04K.
  • Pacer Advisors first reported a position in iTeos Therapeutics in Q1 2021 and held it in 3 quarters.
  • Pacer Advisors's iTeos Therapeutics position peaked at $14.3M in Q1 2022.
  • 150 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2024.

Based on Pacer Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.